Literature DB >> 3530414

Galactose epimeraseless mutants of Salmonella typhimurium as live vaccines for calves.

R C Clarke, C L Gyles.   

Abstract

The purpose of the study was to evaluate the safety and efficacy of a galactose epimeraseless mutant of Salmonella typhimurium administered as an oral vaccine to one week old calves and to investigate properties of galactose epimeraseless mutants which affect their virulence and immunogenicity. The galactose epimeraseless mutant S. typhimurium strain G30D caused diarrhea and fever in three calves to which it was administered orally at a dose of 10(10) organisms; all three calves died following challenge with virulent S. typhimurium ten days postvaccination. Mild illness developed in four calves vaccinated with a dose of 9 X 10(6) organisms and one of these calves survived challenge. Three unvaccinated calves died following challenge. The vaccine organism persisted in tissues and was shed for a prolonged period by calves which received 10(10) organisms. Studies of characteristics of galactose epimeraseless mutants of S. typhimurium showed that, in the presence of galactose, there is selection for secondary mutants which are galactose resistant. The studies indicate that galactose epimeraseless mutants of S. typhimurium are not good candidate live vaccine organisms for use in calves.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3530414      PMCID: PMC1255184     

Source DB:  PubMed          Journal:  Can J Vet Res        ISSN: 0830-9000            Impact factor:   1.310


  17 in total

1.  Immunity in experimental salmonellosis. 3. Comparative immunization with viable and heat-inactivated cells of Salmonella typhimurium.

Authors:  R Germanier
Journal:  Infect Immun       Date:  1972-05       Impact factor: 3.441

2.  Two types of immunity in experimental typhoid; "cellular immunity" and "humoral immunity".

Authors:  D Ushiba
Journal:  Keio J Med       Date:  1965-06

3.  Immunological responses of young animals. II. Antibody production in calves.

Authors:  A N Smih; D G Ingram
Journal:  Can Vet J       Date:  1965-09       Impact factor: 1.008

4.  Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine.

Authors:  R Germanier; E Füer
Journal:  J Infect Dis       Date:  1975-05       Impact factor: 5.226

5.  Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a liver oral vaccine.

Authors:  R H Gilman; R B Hornick; W E Woodard; H L DuPont; M J Snyder; M M Levine; J P Libonati
Journal:  J Infect Dis       Date:  1977-12       Impact factor: 5.226

6.  The immunization of mice and calves with gal E mutants of Salmonella typhimurium.

Authors:  C Wray; W J Sojka; J A Morris; W J Brinley Morgan
Journal:  J Hyg (Lond)       Date:  1977-08

7.  Uridinediphosphogalactose-4-epimerase deficiency in Salmonella typhimurium and its correction by plasmoid-borne galactose genes of Escherichia coli K-12: effects on mouse virulence, phagocytosis, and serum sensitivity.

Authors:  V Krishnapillai
Journal:  Infect Immun       Date:  1971-09       Impact factor: 3.441

8.  Immunity in Experimental Salmonellosis I. Protection Induced by Rough Mutants of Salmonella typhimurium.

Authors:  R Germanier
Journal:  Infect Immun       Date:  1970-09       Impact factor: 3.441

9.  Immunization of animals with gal E mutants of "Salmonella typhimurium".

Authors:  C Wray; W J Sojka; D G Pritchard; J A Morris
Journal:  Dev Biol Stand       Date:  1983

10.  Aromatic-dependent "Salmonella sp." as live vaccine in mice and calves.

Authors:  B A Stocker; S K Hoiseth; B P Smith
Journal:  Dev Biol Stand       Date:  1983
View more
  11 in total

Review 1.  Capsule-mediated immune evasion: a new hypothesis explaining aspects of typhoid fever pathogenesis.

Authors:  Manuela Raffatellu; Daniela Chessa; R Paul Wilson; Cagla Tükel; Mustafa Akçelik; Andreas J Bäumler
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

2.  Contribution of Salmonella typhimurium virulence factors to diarrheal disease in calves.

Authors:  R M Tsolis; L G Adams; T A Ficht; A J Bäumler
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

3.  A galE via (Vi antigen-negative) mutant of Salmonella typhi Ty2 retains virulence in humans.

Authors:  D M Hone; S R Attridge; B Forrest; R Morona; D Daniels; J T LaBrooy; R C Bartholomeusz; D J Shearman; J Hackett
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

4.  Vaccination of calves with a diaminopimelic acid mutant of Salmonella typhimurium.

Authors:  R C Clarke; C L Gyles
Journal:  Can J Vet Res       Date:  1987-01       Impact factor: 1.310

Review 5.  New technologies in using recombinant attenuated Salmonella vaccine vectors.

Authors:  Roy Curtiss; Wei Xin; Yuhua Li; Wei Kong; Soo-Young Wanda; Bronwyn Gunn; Shifeng Wang
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

6.  Oral vaccination of calves with an aromatic-dependent Salmonella dublin (O9,12) hybrid expressing O4,12 protects against S. dublin (O9,12) but not against Salmonella typhimurium (O4,5,12).

Authors:  T Segall; A A Lindberg
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

7.  Cloning and characterization of the galE locus of Pasteurella haemolytica A1.

Authors:  M D Potter; R Y Lo
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

8.  Molecular cloning, sequence analysis and homology modeling of galE encoding UDP-galactose 4-epimerase of Aeromonas hydrophila.

Authors:  Shivani Agarwal; Keshav Gopal; Gagan Chhabra; Aparna Dixit
Journal:  Bioinformation       Date:  2009-11-17

9.  Immune response of pigs to parenteral vaccination with an aromatic-dependent mutant of Salmonella typhimurium.

Authors:  J S Lumsden; B N Wilkie
Journal:  Can J Vet Res       Date:  1992-10       Impact factor: 1.310

10.  Plasmids of Salmonella muenster and their relation to virulence.

Authors:  R C Clarke; S T Jørgensen; N M Harnett; C L Gyles
Journal:  Can J Vet Res       Date:  1987-10       Impact factor: 1.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.